Patents by Inventor Robert F. Kaiko

Robert F. Kaiko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9642850
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: May 9, 2017
    Assignee: PURDUE PHARMA L.P.
    Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
  • Publication number: 20170056393
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Application
    Filed: November 15, 2016
    Publication date: March 2, 2017
    Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
  • Publication number: 20170020865
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Inventors: Robert F. KAIKO, Robert D. COLUCCI
  • Patent number: 9474750
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: October 25, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20160220559
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Application
    Filed: September 8, 2015
    Publication date: August 4, 2016
    Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
  • Publication number: 20160051539
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: November 3, 2015
    Publication date: February 25, 2016
    Inventors: Robert F. KAIKO, Robert D. Colucci
  • Patent number: 9205082
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 8, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20150157625
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Application
    Filed: July 15, 2014
    Publication date: June 11, 2015
    Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
  • Publication number: 20150025101
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: September 18, 2014
    Publication date: January 22, 2015
    Inventors: Robert F. KAIKO, Robert D. COLUCCI
  • Patent number: 8936808
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: January 20, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Patent number: 8932630
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: January 13, 2015
    Assignee: Purdue Pharma L.P
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20150005336
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: September 18, 2014
    Publication date: January 1, 2015
    Inventors: Robert F. KAIKO, Robert D. Colucci
  • Publication number: 20140357658
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: August 15, 2014
    Publication date: December 4, 2014
    Inventors: Robert F. KAIKO, Robert D. Colucci
  • Patent number: 8822487
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: September 2, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20140200236
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: March 14, 2014
    Publication date: July 17, 2014
    Applicant: PURDUE PHARMA L.P.
    Inventors: Robert F. KAIKO, Robert D. Colucci
  • Patent number: 8673355
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: March 18, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20140073663
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Application
    Filed: November 14, 2013
    Publication date: March 13, 2014
    Applicant: PURDUE PHARMA L.P.
    Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
  • Publication number: 20120165359
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: December 27, 2011
    Publication date: June 28, 2012
    Applicant: PURDUE PHARMA L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Patent number: 8105631
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: January 31, 2012
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20110288112
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Application
    Filed: September 22, 2010
    Publication date: November 24, 2011
    Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko